PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer	Breast Cancer Metastatic	Active, not recruiting	Phase 3	2024-09-25		NCT06612814

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Affiliated Hospital of Nantong University	71
Chongqing University Cancer Hospital	41
First Affiliated Hospital Xi'an Jiaotong University	142
First Hospital of China Medical University	92
Fujian Medical University Union Hospital	108
Liaoning Cancer Hospital & Institute	53
Ningbo Medical Center Lihuili Hospital	61
Northern Jiangsu People's Hospital	51
Peking University Cancer Hospital & Institute	189
Shanghai 6th People's Hospital	60
Shanghai First Maternity and Infant Hospital	18
Sun Yat-sen University	606
Zhimin Shao	2

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
breast cancer institute of Fudan University Cancer Hospital	Shanghai	China	1